Renin-angiotensin-aldosterone system (RAAS) blockade may reduce levels of biomarkers of chronic low-grade inflammation and endothelial dysfunction. We investigated the effect of spironolactone added to standard RAAS blockade on these biomarkers in an analysis of four original studies. Materials and methods: The studies were double-blind, randomised, placebo-controlled studies in 46 type 1 and 23 type 2 diabetic patients with micro-or macroalbuminuria treated with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB), and randomised to additional treatment with spironolactone 25 mg and placebo daily for 60 days. Outcome measures: Changes in inflammatory (hsCRP, s-ICAM, TNFα, IL-6, IL-8, Serum amyloid A, IL1β), endothelial dysfunction (sE-selectin, s-ICAM1, s-VCAM1, VWF, p-selectin, s-thrombomodulin) and NT-proBNP after each treatment period. Results: During spironolactone treatment, u-albumin excretion rate was reduced from 605 (411-890) to 433 (295-636) mg/24 h, as previously reported. Markers of inflammation and endothelial dysfunction did not change; only changes in NT-proBNP (reduced by 14%, p=0.05) and serum amyloid A (reduced by 62%, p=0.10) were borderline significant. Discussions: Our results indicate that the renoprotective effect of spironolactone when added to RAAS blockade is not mediated through anti-inflammatory pathways since markers of inflammation and endothelial dysfunction are not affected during treatment.
Introduction
Diabetic nephropathy develops in 30-40% of diabetic patients 1 and is associated with a higher risk of other micro-and macrovascular complications: neuropathy, retinopathy and cardiovascular disease, and with increased all-cause mortality. The increased morbidity and mortality in patients with diabetic nephropathy is partly due to the development of end-stage renal disease (ESRD) and cardiovascular disease, 1 but some studies have shown that it might in part also be mediated through inflammatory activity 2,3 and endothelial dysfunction. 4 In patients with micro-or macroalbuminuria (urinary (u)-albumin excretion rate >30 or >300 mg/24 hours (h), respectively), blockade of the renin-angiotensin-aldosterone system (RAAS) has mainly focused on inhibition of the angiotensin-converting enzyme (ACE) and angiotensin II receptor blockade (ARB), which has been found to reduce the development and progression of diabetic nephropathy 5 and preserve renal function. 6, 7 In experimental studies, aldosterone has been found to cause kidney damage by inducing inflammation, fibrosis and necrosis. 8, 9 Among patients receiving ACE or ARB blockade, 40% develop "aldosterone breakthrough" where aldosterone levels are relatively high despite RAAS treatment, and the extent of aldosterone breakthrough is related to a decline in glomerular filtration rate (GFR). 10, 11 Both in type 1 and type 2 diabetes, spironolactone has been found to lower albuminuria and thus potentially be renoprotective when added to standard treatment including angiotensin-converting enzyme inhibitors (ACE inhibitors) or ARBs as shown in our previous studies, [12] [13] [14] although long-term studies are lacking.
In clinical trials, markers of chronic low-grade inflammation and endothelial dysfunction were shown to be reduced by spironolactone in rheumatoid arthritis 15 and by eplerenone in essential hypertension. 16 From previous long-term prospective studies we have seen that in type 1 2 and type 2 diabetes, 4 lower levels of markers of endothelial dysfunction and inflammation are associated with a better outcome regarding cardiovascular morbidity, renal disease and all-cause mortality. Moreover, a study in patients with microalbuminuria and type 2 diabetes has shown that high levels of markers of inflammation and endothelial damage are associated with the development of diabetic nephropathy. 17 In an attempt to evaluate the known beneficial renoprotective effect of spironolactone when added to standard renoprotective treatment including RAAS blockade, we investigated the serum levels of markers of low-grade inflammation, endothelial dysfunction and N-terminal-pro brain natriuretic peptide (NT-proBNP) in patients with diabetes and elevated urinary albumin excretion.
Materials and methods
Four studies with identical design were carried out at Steno Diabetes Center. We previously performed these four studies including patients with either type 1 or type 2 diabetes who had different levels of albuminuria (micro-, macro-and nephrotic range albuminuria) in Table 1 . Since the studies had identical design, we were able to pool the data for this substudy of biomarkers in diabetic patients with elevated albumin excretion rate. The study by Schjoedt et al. 18 is based on merging the two studies of type 1 diabetic 12 and type 2 diabetic patients 13 with macroalbuminuria and adding eight more patients with nephrotic range albuminuria. This was done to investigate the subgroup of patients with nephrotic range albuminuria. The fourth study was in patients with type 1 and diabetes and microalbuminuria; this was recently published. 14 The studies were randomised, double-blind, placebocontrolled, crossover studies consisting of two treatment periods. In random order, patients received spironolactone 25 mg once daily for one period of 60 days and matching placebo tablets once daily for another 60 days. During the 0-to 28-day screening period, it was ensured that patients were in optimal antihypertensive treatment. There was no drug washout period between treatment periods ('active washout'). 19 The study medication was added to the patients' usual antihypertensive treatment, including an RAAS-blocking agent (ACE inhibitor and/or ARB) in recommended doses in all patients. The type and dose of prior antihypertensive treatment, including diuretics, remained unchanged throughout the study. At the end of each treatment period, the primary endpoint urinary albumin excretion rate, and the secondary endpoints, blood pressure, GFR and serum biomarkers of endothelial damage and inflammation were determined.
Dietary intake of protein and salt was not restricted; however, all patients were given written and oral information on how to lower potassium intake in their diet to lower the risk of hyperkalaemia associated with the combination of ACE inhibition or ARB and spironolactone. The study was performed according to the Declaration of Helsinki and approved by the ethical committee of Copenhagen County. All patients gave their informed consent.
We included 69 Caucasian diabetic patients, 46 with type 1 diabetes and 23 with type 2 diabetes. The patients had persistent micro-or macroalbuminuria (u-albumin excretion >30 mg/24 h in two of three consecutive 24-h urine collections) during treatment with an ACE inhibitor or an ARB in optimal recommended doses. Patients' ages were between 18 and 80 years.
Exclusion criteria were plasma (p) potassium > 4.5 12, 13, 18 or > 4.7 mmol/l, 14 pregnancy, breastfeeding, alcohol or medicine abuse, and allergy to ACE inhibitor, ARB, or spironolactone, treatment with aldosterone antagonists and GFR < 30 ml/min/1.73m 2 . The exclusion criteria during the study were increase an in p creatinine of > 35% within the first two weeks of treatment, or p potassium > 5.5 12, 13, 18 or 5.7 14 mmol/l at any time.
Laboratory procedures
Albuminuria was determined in three consecutive 24-h urine collections, completed immediately before the end of each treatment period (Turbidimetry, Hitachi 912 System; Roche Diagnostics, Mannheim, Germany). From 24-h urine collections sodium, potassium, creatinine and urea excretion were determined (Hitachi 912 System; Roche Diagnostics). To evaluate the kidney function after each treatment period, GFR was measured after a single intravenous injection of 3.7 MBq 51 Cr-EDTA at 8:30 a.m. by determining the radioactivity in venous blood samples taken 180, 200, 220 and 240 minutes after injection. 20 The results were standardised for 1.73 m 2 body surface area using the patients' surface area at the start of the study. The mean day-to-day coefficient of variation was 4% in our laboratory.
Blood samples for p renin and aldosterone concentrations were taken after 30 minutes of supine rest. P aldosterone was measured using a commercially available radioimmunoassay (Coat-a-Count; Diagnostic Products Corporation, Los Angeles, CA, USA).
The markers of endothelial dysfunction, NT-proBNP and inflammation were measured in all 21 type 1 diabetes patients with microalbuminuria, 14 whereas not all markers were measured in all 69 patients (see Tables 2 and 3 for the full list). Table 2 includes all patients, whereas Table 3 shows the results for the markers measured in the subset of 21 patients. All 69 patients had high-sensitivity C-reactive protein (hs-CRP), NT-proBNP, von Willebrand factor (vWf), solubleE-selectin (sE-selectin), solubleintercellular adhesion molecule (s-ICAM1) and soluble vascular cell adhesion molecule1 (sVCAM1) measured, whereas the 21 microalbuminuric patients 14 also had interleukin-6 (IL-6), interleukin-8 (IL-8), serum amyloid A (SAA), interleukin1β (IL1β), p-selectin and s-thrombomodulin measured.
All markers were measured with MSD multipanel measurements or enzyme-linked immunosorbent assay (ELISA).
Serum concentrations of NT-proBNP were analysed on the Elecsys 2010 platform by an electrochemiluminescence method. 21 Hs-CRP and vWf were measured with highly sensitive sandwich immunoassays and s-VCAM-1, s-ICAM-1 and sE-selectin by use of commercially available ELISA kits. All measurements of the biomarkers were performed in serum except vWf, which was measured in p.
The intra-assay variation in our analyses was: IL-1β: 14.8%, IL-6: 5.3%, IL-8: 5.6%, tumour necrosis factor (TNF)-α: 5.0%, sE-selectin 4.0%, p-selectin: 4.7%, s-thrombomodulin: 3.9%, vWF: 3.1%, CRP: 4.5%, SAA: 3.7%, s-ICAM1: 2.8%, s-VCAM: 2.7% and NT-proBNP: 4.9%. Interassay variation was: IL-1β: 28.9%, IL-6: 13.6%, IL-8: 8.5%, TNF-α: 9.1%, sE-selectin 7.0%, p-selectin: 8.5%, s-Thrombomodulin: 7.1%, vWF: 7.7%, CRP: 4.1%, SAA: 10.8%, s-ICAM1: 5.2%, s-VCAM: 5.8% and NT-proBNP: not done. All samples were measured on one plate (for each marker).
Statistical analysis
Normally distributed variables are expressed as mean SD or mean SEM. Changes in variables between visits are expressed as means with 95% confidence interval (CI). Albuminuria and markers of inflammation, endothelial dysfunction and NT-proBNP were logarithmically transformed before statistical analysis owing to their skewed distribution and are given as geometric means (95% CI). Changes in these variables during treatment with spironolactone as compared to placebo are expressed in percentages. All comparisons of normally or log normally distributed 
Results
Sixty-nine diabetic patients were randomised in the study and all completed the study. Mean age was 53 (11) years and 16 were female. Forty-six had type 1 diabetes and 23 had type 2 diabetes (Tables 1 and 2 ). The patients had either micro-(n=21) or macroalbuminuria (n=48), of whom 20 patients had nephrotic range albuminuria (u-albumin excretion > 2500 mg/24 h). All patients received RAAS blocking agents and stable doses of diuretics. There were no changes in antihypertensive medication during the entire study period. As previously published, spironolactone treatment reduced the primary endpoint, urinary albumin excretion rate, measured in three consecutive 24-h urine collections, by 28%, from 605 mg/24 h to 433 mg/24 h (p < 0.001) [12] [13] [14] 18 ( Table 2 ). During treatment, p aldosterone was significantly increased, from 31 (24-39) pg/ml to 63 (53-77) pg/ml, p<0.001.
The data on all 69 patients and biomarkers are shown in Table 2 . We found that the markers of low-grade inflammation hs-CRP and s-ICAM1 did not change during spironolactone treatment compared to placebo, p = 0.4 and p = 0.8, respectively. The biomarkers of endothelial dysfunction, sE-selectin, s-ICAM1, s-VCAM1 and p-vWF did not change either; they increased slightly by around 0 to 3 %, p > 0.4. NT-proBNP levels decreased by 14% (-26 to 0, p = 0.054) during spironolactone treatment.
In the study of 21 microalbuminuric patients (Table 3) , SAA decreased with 62% during spironolactone treatment, although not significantly (p = 0.1). The other markers of low-grade inflammation, TNFα, IL-6, IL-8 and IL1beta, did not change at all, i.e. were not affected by spironolactone treatment (p > 0.24). Regarding the biomarkers of endothelial dysfunction; s-P-selectin and s-thrombomodulin, spironolactone did not affect the levels of these either (p > 0.5). There was no effect on measured biomarkers when stratifying patients into those with good response of spironolactone treatment (largest decrease in u-albumin excretion during treatment) or the largest changes in p-aldosterone levels (data not shown).
Discussion
We performed four randomised double-blind placebo-controlled cross-over intervention studies with spironolactone treatment in diabetic patients with elevated urinary albumin excretion already on RAAS blockade with ACE inhibitor or ARB. Changes in markers of inflammation, endothelial dysfunction and NT-proBNP were investigated in order to see if reduction in albuminuria was associated with changes in these markers. The intervention with spironolactone did not affect the markers of inflammation, endothelial dysfunction or NT-proBNP significantly. This was despite a significant reduction in albuminuria by spironolactone.
Aldosterone induces pro-sclerotic factors such as transforming growth factor (TGF)-β1 and decreased macrophage infiltration leading to renal fibrosis and urinary albumin excretion.
During treatment with an ACE inhibitor or an ARB, aldosterone secretion is initially suppressed, but 40% of all patients have "aldosterone escape phenomenon" 22 or more correctly "aldosterone breakthrough." 10 Therefore, it has been considered appropriate to block the effects of aldosterone by adding spironolactone to recommended treatment with ACE inhibitors or ARBs. Based on animal studies, the mechanism for the additional effect on urinary albumin excretion during spironolactone treatment has been suggested to be reduced production of the mentioned pro-sclerotic factors. 9 In a previous post-hoc analysis of the IRMA2 studies, we analysed the value of inflammation markers (hs-CRP, IL-6, fibrinogen) and endothelial dysfunction markers (vWf, s-VCAM-1, s-ICAM-1, sE-selectin) for the prediction of progression to diabetic nephropathy (u-albumin>300 mg/24 h). We found that especially markers of endothelial dysfunction were shown to be independently associated with progression of kidney disease. 17 From this it seems reasonable to assume that by diminishing levels of endothelial dysfunction, the progression or initiation of diabetic nephropathy is inhibited.
Blockade of the RAAS with the ACE-inhibitor enalapril or ARB irbesartan in high-risk patients (coronary artery disease or type 2 diabetes and microalbuminuria) has been shown to affect some markers of low-grade inflammation and endothelial dysfunction in a favourable way. 23, 24 Both studies used maximally effective doses of irbesartan or losartan. However, not all markers of inflammation and endothelial dysfunction were reduced; five out of eight biomarkers in the subgroup analysis of the IRMA2 study mentioned above 24 by Persson et al. were not affected by irbesartan treatment (sICAM1, sVCAM1, sE-selectin, TGFβ, AGE-peptides). In experimental settings it has been shown that aldosterone antagonism reduces the production of proinflammatory cytokines (using spironolactone) 25 and attenuates renal damage and inflammation (using eplerenone). 26 Furthermore, spironolactone has been shown to prevent diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. 27 These results conflict partly with our study in that we did not find an effect on inflammatory or endothelial markers. However, in the above-mentioned clinical studies 23, 24 high doses of RAAS blockade were used; this is in contrast to our study, which used the lowest dose of spironolactone on top of RAAS blockade. This dose was, however, sufficient to provide additional renoprotection, e.g. diminish urinary albumin excretion. Moreover, we added spironolactone/placebo on top of maximal antihypertensive and renoprotective treatment whereas in the IRMA2 study the patients were only prescribed either placebo or irbesartan on top of non-RAAS blocking antihypertensive agents. 24 This means that in our study patients might already receive maximal "antiinflammatory" treatment during the placebo period, and therefore the design of the present study might not be optimal to evaluate the individual effect of spironolactone.
Others found, similar to our results, no effect of spironolactone treatment (12.5 mg-50 mg) on hs-CRP in patients with heart disease. 28 NT-proBNP was not significantly reduced during treatment. The lack of changes in markers of inflammation and endothelial dysfunction could indicate that the renoprotective effect of spironolactone 25 mg is not mediated through anti-inflammatory or endothelial function-improving pathways. We cannot exclude, however, that changes in inflammatory or endothelial markers in the tissues are insufficiently reflected by the values measured in serum. This needs further testing in other studies.
In our study aldosterone levels were compensatorily increased during spironolactone treatment as also seen in other clinical studies 18 ; this could also contribute to inflammation and endothelial dysfunction via pathways not blocked by spironolactone, although we did not see an increase in markers of inflammation and endothelial dysfunction in the present study. Previous studies have demonstrated that usage of spironolactone is safe and beneficial. 29, 30 In conclusion, our study shows that adding spironolactone 25 mg daily to treatment with RAAS blockade in diabetic patients with elevated urinary albumin excretion does not affect markers of endothelial damage, inflammation or NT-proBNP.
